Professional Documents
Culture Documents
INR 950 INR 950: Swot Pestle
INR 950 INR 950: Swot Pestle
INR 950 INR 950: Swot Pestle
Menu '
SWOT PESTLE
GSK began its successful journey as an apothecary shop
in London since then the company's driving force has
been innovation. From a group of individual
entrepreneurs to a global organization of around
100,000 employees, GSK has discovered, developed, and
commercialized a variety of medicines, vaccines and
healthcare products that constitute the pillars of today’s
GSK. GlaxoSmithKline is a science-led global health care
company whose core values are patient focus,
transparency, respect, and integrity. Therefore, the
SWOT report is essential to manifest a discussion on all
the pertinent internal strategic factors of GSK that
contribute to the trajectory growth of the company. The
SWOT Analysis of GSK substantiates the company's
current major strengths and opportunities from its
external environment that can be consolidated to
further strengthen the company. The report also
bestows intelligence on GSK's internal weaknesses and
external threats that can cripple its growth.
The core competency of GSK and one of its major
strengths is its strong Research & Development wing
that presents the company with a competitive edge over
its rivals. In 2018 the company has invested around £3.9
billion in R&D to focus on scienti#c research related to
the immune system, human genetics, and advanced
technologies. Apart from strong R&D capabilities
internal factors like global presence, strong distribution
and sales network, joint ventures, a broad array of
products, etc., are quintessential strengths of GSK.
GSK has come under a scanner for a health-care fraud
case of promoting drugs for unapproved uses and
failure to report safety data. These healthcare fraud
allegations are not only a mere weakness of a
healthcare company but also supremely dent the
reputation of the company extensively.
GSK seeks opportunities in collaborating with renowned
companies, for instance in 2019 GSK announced a #ve-
year collaboration with Lyell Immunopharma, a San
Francisco biotechnology company, to develop new
technologies to enhance cell therapies for cancer
patients. Launching new products is another great
opportunity for growth of the pharma company. GSK
encompasses this opportunity by strengthening its
product pipeline and introducing advanced assets in
Respiratory, HIV and, notably, Oncology sectors. GSK's
pharmaceutical and consumer products face stringent
competition threat from top industry players, creating
limited market share and price wars. Also, generic drugs
have become a threat to pharmaceutical companies as
their demand, sales and availability are increasing.
The SWOT analysis for GlaxoSmithKline is presented
below in a matrix followed by the detailed analysis:
Strengths Weaknesses
Opportunities Threats
( (
Sample Complete Free Summary Report
Report
Weaknesses
Major Brands :
Pharmaceutical products
Calpol, others
Vaccine
Havrix (for hepatitis A)
Rotarix (for human rotavirus)
Typherix (for typhoid)
( (
Sample Complete Free Summary Report
Report
WH
WHYY B
BUY
UY TH
THIS
IS TA
TABLE
BLE OF
OF DELIVERY
DELIVERY AND
AND WHY
WHY CHO
CHOOS
OSEE
REPORT
REPORT?? CONTEN
CONTENTSTS FORMAT
FORMAT US?
US?
Euro#ns Scienti#c
Novo Nordisk
Medtronic
Sano#
CSL Limited
View All
View All
View All
ADVERTISE WITH US
ORDER
NOW
TESTIMONIALS
Proceed
ADVERTISE WITH US
Proceed
GO TO TOP
1
Copyright © 2021. All Rights Reserved by
Barakaat Consulting.
➤
! " # $